This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Merck, Salesforce & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More
by Zacks Equity Research
Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.
Voyager (VYGR) Gains on Gene Therapy Deal With Novartis
by Zacks Equity Research
Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.
Novartis (NVS) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Novartis (NVS) stood at $101, denoting a +0.03% change from the preceding trading day.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.
Novartis (NVS) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Novartis (NVS) closed at $99.71 in the latest trading session, marking a +1.18% move from the prior day.
The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours
by Zacks Equity Research
Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours are part of the Zacks top Analyst Blog.
Novartis (NVS) Stock Moves -1.17%: What You Should Know
by Zacks Equity Research
Novartis (NVS) closed the most recent trading day at $97.14, moving -1.17% from the previous trading session.
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
by Zacks Equity Research
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
Novartis (NVS) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Novartis (NVS) closed at $98.87, indicating a -0.84% shift from the previous trading day.
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
by Kinjel Shah
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.
Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More
by Kinjel Shah
AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.
Why Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
by Ekta Bagri
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
by Zacks Equity Research
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
3 Large Drug Stocks That Have Outperformed Industry YTD
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
by Zacks Equity Research
Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.
Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
by Zacks Equity Research
Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.
The Zacks Analyst Blog Highlights Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals
by Zacks Equity Research
Procter & Gamble, Novartis, Mondelez International, Elevance Health and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Top Stock Reports for Procter & Gamble, Novartis & Mondelez International
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novartis AG (NVS) and Mondelez International, Inc. (MDLZ).
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues.